Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in maine

J Infect Dis. 2012 Oct 1;206(7):1059-68. doi: 10.1093/infdis/jis441. Epub 2012 Jul 30.

Abstract

Background: In late October 2009, school-located pandemic vaccination was initiated in Maine before or concurrent with 2009 pandemic influenza A (H1N1) virus (pH1N1) peak activity.

Methods: A case-control evaluation of 2009 H1N1 vaccine effectiveness was conducted in schools in Cumberland County, Maine. A case was a child who had an acute respiratory illness during 2 November-18 December 2009, and who tested positive for pH1N1 by real-time reverse-transcription polymerase chain reaction (rRT-PCR). For each case, ≥ 4 event time-matched controls were sampled among classmates present in school during the study period who did not have an influenza-like illness. Vaccine effectiveness was calculated as (1 - adjusted odds ratio [aOR])100%; aOR was estimated by using weighted logistic regression.

Results: After adjusting for a diagnosis of asthma, 1 dose of 2009 H1N1 vaccine provided 69% protection (95% confidence interval (CI), 13-89) against rRT-PCR-confirmed H1N1 infection. Vaccine effectiveness estimates for live attenuated and inactivated vaccine were 81% (95% CI, -37 to 97), and 58% (95% CI: -39 to 87), respectively.

Conclusions: One dose of monovalent pandemic vaccine provided substantial protection against pH1N1 infection among school-aged children.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Influenza A Virus, H1N1 Subtype / genetics
  • Influenza A Virus, H1N1 Subtype / immunology*
  • Influenza Vaccines / administration & dosage*
  • Influenza, Human / epidemiology
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control*
  • Logistic Models
  • Maine / epidemiology
  • Male
  • Pandemics / prevention & control*
  • RNA, Viral / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Treatment Outcome
  • Vaccines, Attenuated / administration & dosage

Substances

  • Influenza Vaccines
  • RNA, Viral
  • Vaccines, Attenuated